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ABSTRACT In much of the developing world, severe malnutrition is the most prev-
alent cause of immunodeficiency and affects up to 50% of the population in some
impoverished communities. As yet, we do not know how severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) will behave in populations with immunodefi-
ciency caused by malnourishment. Interestingly, researchers are now speculating
that, in some instances, a defective cellular immune system could paradoxically be a
protective factor against severe disease in certain patients contracting SARS-CoV and
SARS-CoV-2. This could be linked to the absence of T-cell activation. Based on avail-
able information presented here, it is plausible that the hyperimmune response, and
subsequent cytokine storm often associated with severe coronavirus disease 2019
(COVID-19), could be “counteracted” by the defective immune response seen in indi-
viduals with malnutrition-induced leptin deficiency. In this paper, we proposed a
theory that although those with malnutrition-linked leptin deficiency are at risk of
SARS-CoV-2 infection, they are at lower risk of developing severe COVID-19.
KEYWORDS COVID-19, SARS-CoV-2, undernutrition, leptin deficiency, cytokine storm,
malnutrition
In most cases, infection with the four common human coronaviruses (HCoVs) causesmild cold-like symptoms, involving the upper respiratory tract. A severe lower respi-
ratory tract infection (LRTI) can, however, develop in immunocompromised patients.
Unlike 229E, OC43, NL63, and HKU1, the more pathogenic severe acute respiratory syn-
drome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus
(MERS-CoV) cause LTRI, accompanied by a cytokine storm in patients with poor prog-
nosis (1).
A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-
2], or 2019-nCoV) has been shown to cause acute respiratory disease syndrome (ARDS)
in humans. The typical clinical symptoms of coronavirus disease 2019 (COVID-19)
include fever, dry cough, shortness of breath, and fatigue. A small percentage of
patients, however, develop various fatal complications, including septic shock, organ
failure, pulmonary edema, severe pneumonia, and ARDS (2). As of 1 December 2020,
COVID-19 has been confirmed in 61.8 million people in more than 200 countries and
territories, resulting in 1.4 million deaths worldwide, a case mortality of approximately
2.3% (3). Now, accumulating evidence suggests that a majority of SARS-CoV-2-positive
patients with severe COVID-19 might also develop a cytokine storm syndrome (4). In
particular, the elderly and people with preexisting medical conditions appear more
susceptible to severe COVID-19 outcome, which may be associated with a cytokine
storm and ARDS (5). There is no consensus definition of “cytokine storm” that encom-
passes all the various therapies, pathogens, cancers, autoimmune conditions, and
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monogenic disorders that can trigger such an event. Nevertheless, it can generally be
regarded as an excessive immune response, one that may be greater than its immedi-
ate benefit, that causes collateral damage to organs, and is accompanied by elevated
levels of circulating cytokines (6). Although the exact cause of the cytokine storm in
severe COVID-19 is not yet clear, it stands to reason that the SARS-CoV-2 virus plays a
central role, since similar features have been observed in SARS-CoV, MERS-CoV, as well
as other viral infections (7). This paper will focus on the immunosuppressive effect of
leptin deficiency-linked malnutrition in the context of SARS-CoV-2, and the concomi-
tant hyperinflammatory response seen in severe COVID-19 (6).
Viral infections can trigger secondary/acquired hemophagocytic lymphohistiocyto-
sis (sHLH)—a hyperinflammatory syndrome—mainly resulting in an unremitting fever,
cytopenias, and pulmonary involvement (including ARDS) in about half of patients (8).
Left untreated, sHLH leads to a cytokine storm and hemophagocytosis, resulting in
fatal hypercytokinemia with multiorgan failure (9). In severe lung infections, the cyto-
kine storm-linked inflammatory response can move into the systemic circulation, pro-
ducing systemic sepsis, which could result in the damage of other organs (10).
Interestingly, severe COVID-19 is associated with a cytokine profile similar to that of
sHLH (11), and increasing evidence shows elevated levels of inflammatory cells, cyto-
kines, chemokines, and other inflammatory mediators associated with severe COVID-
19 (1, 12–14). Since COVID-19 also closely resembles SARS, and ARDS progression in
severe SARS is marked by a similar elevation in inflammatory cytokines, it is reasonable
to conclude that similar immunopathogenic features are to be expected in severe
COVID-19 cases (15). Although ARDS and the accompanying respiratory failure are the
leading causes of death in severe COVID-19 cases, the hyperinflammatory response
from the cytokine storm facilitates the immunopathology that culminates in ARDS and
respiratory failure (16). In fact, inflammation from the hyperactivated immune response
increases capillary permeability and damages the alveolar-capillary membrane, bring-
ing about pulmonary edema, impairing gas exchange, and often culminating in respi-
ratory failure, characteristic features of ARDS (1, 17).
Malnutrition, and protein energy malnutrition (PEM) in particular, has been linked to
an immunosuppressive phenotype. This phenotype is characterized by reduced proin-
flammatory cytokines, notably interleukin 2 (IL-2), IL-6, IL-12, gamma interferon (IFN-g), tu-
mor necrosis factor alpha (TNF-a); an impaired response from inflammatory T-cells
(CD691, CD251), dendritic cells (DCs) (HLA-DR1), and macrophages (CD141) upon stimu-
lation; and a concomitant increase in anti-inflammatory cytokines, such as IL-4, IL-10, and
transforming growth factor beta (TGF-b) (18–20). These studies demonstrate that PEM
brings about an immunological shift in the balance of cytokines, favoring an anti-inflam-
matory response, and this is in stark contrast to what has been reported for a cytokine
storm; a hyperinflammatory event in which proinflammatory cytokine levels are increased
and those of anti-inflammatory cytokines are decreased (Fig. 1). Clearly, the cytokine pro-
file of persons suffering from PEM is inverse to that of a cytokine storm, as many of the
damaging, proinflammatory cytokines from the storm are inversely regulated to anti-
inflammatory cytokines. This immunosuppressive phenotype, however, gives rise to a
phenomenon called “immunoparalysis” —a persistently high anti-inflammatory immune
response following infection. Since a proper immunological balance between pro- and
anti-inflammatory processes is vital for recovery from critical illness, it has been proposed
that patients who survive the cytokine storm, but subsequently die, may be those who
did not recover from immunoparalysis (21). Accordingly, malnutrition does not necessarily
protect against COVID-19 itself but rather appears to counteract the severe complications
brought on by the cytokine storm as a consequence of the infection.
Malnourished individuals commonly have decreased levels of the adipokine, viz.
leptin, and this deficiency in leptin has been linked to the impaired immune function
typically seen in malnourished persons (22–24). Leptin has been shown to shift the
immune response from an anti-inflammatory profile to a more proinflammatory one,
validating the observed immunosuppressive phenotype seen in such leptin-deficient
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malnourished persons (25, 26). This effect has been demonstrated in animal models
and other infectious diseases, where subsequent administration of leptin also reversed
the effects of leptin deficiency observed on immunosuppression (6, 27). This specifi-
cally demonstrated that severe protein-restricted (malnourished) BALB/c mice, infected
with visceral leishmaniasis, expressed significantly higher levels of anti-inflammatory
cytokines (IL-4, IL-10, and TGF-b) compared to infected mice on a regular protein diet.
Subsequent administration of leptin to these malnourished, infected mice significantly
decreased the expression of IL-4, IL-10, and TGF-b , directly implicating leptin in shifting
the immune response from an anti-inflammatory profile to a proinflammatory one.
Human clinical studies on malnutrition-linked immunodeficiency would, therefore,
benefit greatly from measuring the leptin levels of malnourished persons and compar-
ing it to that of well-nourished persons to determine whether such a significant differ-
ence could support the observed differences in their immunological profile. One study
measured the serum leptin levels in both SARS-CoV-2-infected and uninfected patients
and reported a positive correlation between the serum leptin levels and body mass
index (BMI) of infected persons (28). Although the authors did not include immunologi-
cal markers, they described a clinical and biological framework in which they proposed
that the increased BMI and accompanying serum leptin levels could explain the need for
FIG 1 Leptin modulates the immune response by acting on both effector T (Teff) cells and regulatory T (Treg) cells. Under
homeostatic conditions, adipocytes secrete basal levels of leptin that positively regulate Th1 immunity through the proliferation of
Teff cells and, simultaneously, regulate Treg cell expansion negatively. This achieves an optimal immune profile—a balance between
Teff and Treg cells, whereby Tregs mediate immune tolerance through anti-inflammatory cytokine production, while Th1 cells confer
protection from infections through proinflammatory cytokine production. Reduced leptin levels (hypoleptinaemia), as a consequence
of weight loss or malnutrition (starvation), reduce Teff cell proliferation and increase Treg cell expansion. This downregulates Th1
immunity and produces an immune response skewed toward an anti-inflammatory profile, increasing a person’s susceptibility to
infections by reducing the Th1-mediated inflammatory response. Accordingly, malnourished persons are predisposed to contracting
infections but can be protected from hyperinflammatory conditions by this anti-inflammatory profile. Conversely, high leptin secretion
(hyperleptinaemia), attributed to increased adipocyte mass as seen in obesity, triggers Teff expansion and reduces Treg cell
proliferation. This skews the immune response toward a proinflammatory profile, increasing the person’s risk to hyperinflammatory
conditions by reducing the Treg-mediated anti-inflammatory response. Accordingly, such persons are predisposed to hyperinflammatory
conditions and can experience more severe inflammatory responses on account of the proinflammatory immune profile. Adapted from
reference 40.
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SARS-CoV-2-infected patients to receive mechanical ventilation, implicating the increased
BMI and serum leptin levels in acute pulmonary inflammation.
Several studies have used BMI as the only marker for obesity. However, we caution
against this. The use of BMI alone as a marker for obesity is an accepted Western norm,
which we recommend should be accompanied by additional adiposity markers such as
waist circumference, waist-to-hip/height ratio, and/or body fat percentage to classify per-
sons more accurately as overweight or obese. Accordingly, S. A. Peters et al. (29) reported
that higher adiposity markers, viz. BMI, waist circumference, waist-to-hip ratio, and waist-
to-height ratio, are associated with a greater risk of mortality from COVID-19. T. Yates
et al. (30) also reported a dose-response association between BMI and waist circumfer-
ence and testing positive for COVID-19, and C. Razieh et al. (31) similarly reported a
difference in the risk of COVID-19 between ethnic groups based on BMI and waist circum-
ference. Furthermore, J. Wang et al. (32) used both BMI and serum leptin levels, reporting
that patients with a high BMI have significantly higher levels of leptin. This is also posi-
tively associated with inflammatory mediators and disease severity in such patients.
Admittedly, we cannot generalize, and our hypothesis might not be applicable to
all developing countries due to innate differences in diet and nutritional states, among
other factors. Also, our hypothesis might not be relevant to all elderly persons in devel-
oping countries since “immunosenescence” and “inflammaging” could also contribute
to COVID-19 age-related mortality. A marked decrease in both CD41 helper T cells—
that help to clear viral infections—and immunosuppressive T cells (Tregs) (“immunose-
nescence”), accompanied by a chronic, low-grade inflammatory state from increased
serum inflammatory mediators (“inflammaging”) would be additional factors relevant
for consideration in this elderly population (33).
Implications of leptin deficiency-induced immunosuppression for biomarkers
and vaccine development. Worryingly, the data from these studies suggest that mal-
nutrition could also cause a deficient vaccine response. The importance of both DCs
and IL-2 in the development of a functional immunological memory strongly suggests
that a reduced vaccine response could likely be the result of impaired DC function,
insufficient IL-2 levels to prime effector memory T cells, and an impaired response from
effector memory T cells that have formed (34, 35). This could also have dire implica-
tions for vaccine administration as immunodeficiency-linked malnutrition might not
simply be “corrected” by vaccination. These studies clearly implicate a metabolic
requirement in the mounting and maintenance of functional immunological memory,
which is paramount to an effective vaccine response (25, 26).
A neglected aspect of the leptin-immune axis that could also have implications for
vaccine development, is the effect of leptin on antibody production. Leptin downregu-
lates antibody production and class switching, and since serum leptin levels are elevated
in both obese and elderly persons, this should be considered to ensure the development
of effective vaccines for these vulnerable groups (36). Interestingly, this study also found
that rapamycin rescues the negative leptin-induced effect on B cells. Furthermore, the
impact of leptin on the immune system and its correlation with disease progression and
severity would make it a valuable predictive tool, or biomarker, for predicting patient
prognosis (32). Naturally, its efficacy as a biomarker would first have to be tested and con-
firmed, but it could prove especially useful in Africa and other developing countries,
where treatments are often sparse and expensive and not everyone has access to primary
health care. Leptin’s use as a biomarker could also assist in developing a risk-based
approach where a patient’s leptin levels could be used to evaluate whether the patient
could benefit from early, prophylactic treatment, such as dexamethasone or any other rel-
evant COVID-approved treatment(s).
In this paper, we proposed that individuals with leptin deficiency-linked immuno-
suppression due to malnutrition are not at higher risk of developing severe COVID-19
compared to healthy, well-nourished individuals with physiologically “normal” leptin
levels. Malnourished persons can still contract COVID-19, but they are less likely to die
from the hyperinflammation brought on by the cytokine storm. Interestingly, research-
ers have now speculated that a defective cellular immune system—as seen in HIV
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patients—“could paradoxically be a protective factor in some patients” contracting
SARS-CoV (37). Similarly, for SARS-CoV-2, “the compromised immunity might be the
reason that HIV/AIDS patients did not occur inflammatory changes and clinical symp-
toms” associated with severe COVID-19 (38), which could be linked to the absence of
T-cell activation (39). Based on available information, it is plausible that the hyperim-
mune response, and subsequent cytokine storm often associated with severe COVID-
19, could be “counteracted” by the defective immune response seen in individuals
with malnutrition-induced leptin deficiency.
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